Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago.
Glenmark Pharmaceuticals Ltd on Thursday said it has slashed the price of breast cancer drug Trastuzumab by bringing its brand Trumab at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier.
Trastuzumab is used in the treatment of a particular type of breast cancer HER2-positive, and the company markets its version in India under the brand name Trumab .
Trastuzumab is used in the treatment of a particular type of breast cancer HER2-positive, and the company markets its version in India under the brand name Trumab . It is now priced at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier.
Get latest articles and stories on Latest News at LatestLY. Glenmark Pharmaceuticals Ltd on Friday reported a 21.3 per cent rise in consolidated profit after tax at Rs 290.8 crore for the third quarter ended December 31, 2022. Latest News | Glenmark Pharma Q3 PAT Rises 21.3 Pc to Rs 290.8 Cr.